Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.46 |
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152154 | 0.82 | PDE4D (0.47) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6609841 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL1223854 | 0.81 | ALDH1A1 (0.47) | — | |
| SCHEMBL8218374 | 0.79 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDGFRB | |
| SCHEMBL8218377 | 0.79 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDGFRB | |
| SCHEMBL8211014 | 0.79 | PDE4D (0.44) | PDE4BPDE4APDE4CPDE4DPDGFRB | |
| SCHEMBL8211017 | 0.79 | PDE4D (0.44) | PDE4BPDE4APDE4CPDE4DPDGFRB | |
| SCHEMBL30389745 | 0.77 | TRPC6 (0.48) | PDGFRBPDGFRA | |
| SCHEMBL72957 | 0.77 | PDE4A (0.58) | PDE4BPDE4APDE4CPDE4DPDGFRB | |
| SCHEMBL8218599 | 0.76 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-0882714-B1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS PHARMACEUTICAL CO (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| US-5935977-A | PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.